This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Stockhead: HealthInvest 2024: The biotech sector looks in rude health, judging by these five ASX innovators
Race Oncology joins four other biotech companies to present at HealthInvest 2024, hosted by IR Department, Morgans and Stockhead.
At the conference, Race presented the clinical development history of its lead asset bisantrene, and the pipeline for the coming months to investors, analysts and industry peers in the room.
Watch the interview with Dr Peter Smith, Race’s Executive Chair below. Full article on the conference can be accessed here.